Skip to content
MARKETS / NASDAQ / DBVT
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

DBV Technologies S.a. DBVT

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.6M
▲ 35.8% YoY
$-146.9M
$-121.7M
In brief

What this company does

Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Our most advanced product candidate is Viaskin® Peanut Patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials. The Company plans a BLA submission in the first half of 2026 for Viaskin Peanut Patch as a potential treatment for children four to seven years old. As of December 31, 2025, we had 125 full-time employees, including approximately 38 with M.D. or Ph.D. degrees, and one part-time employee.

Written from the business description in DBV Technologies S.A.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
USD 5.6M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.6 · Net income -146.9
40M80M-80M-160M2019202020212022202320242025
Compound annual growth
+5.2%
−13.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −13.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−2607 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2609.2% · Net -2607.3%
500%1000%1500%-1000%-2000%2019202020212022202320242025
ROE
FY2025 · ROE -149.8%
20%40%60%-50%-100%2019202020212022202320242025

Each USD of equity lost 150 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -121.7
-80M-160M2019202020212022202320242025

Total assetsUSD 233.7M
EquityUSD 168.8M
CashUSD 194.2M
Current ratio3.67×

Equity funds 72% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.2−0.2
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.2·
Income tax $B0.00.00.00.0−0.0−0.00.0
Net income $B−0.1−0.10.10.1−0.1−0.2−0.2
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.2−0.2
EPS, diluted $−1.05−1.17−0.76−1.24−1.78−2.95−4.65
Dividend / sh $·······
Payout %·······
ROE %−149.8−136.043.565.6−64.2−80.0−103.6
Shares out B·0.10·····

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 2 failures in 29 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 47 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inoutside the United States — SEC code I0
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image